Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Marsh

Showing results (641-650 of 654) with videos related to

Pageof 66
Sort By:
Journal of Medicinal Chemistry|January 11, 2008
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitorGang Zhao, Andrew J Souers, Martin Voorbach, et al.
Bioorganic & Medicinal Chemistry|May 27, 2008
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic painIrene Drizin, Robert J Gregg, Marc J C Scanio, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylaminesAndrew J Souers, Rajesh R Iyengar, Andrew S Judd, et al.
Journal of Medicinal Chemistry|October 27, 2006
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safetyJohn K Lynch, Jennifer C Freeman, Andrew S Judd, et al.
International Journal for Parasitology|April 1, 2020
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learnedRyan Choi, Matthew A Hulverson, Wenlin Huang, et al.
Journal of Medicinal Chemistry|January 8, 2008
Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory painMichael E Kort, Irene Drizin, Robert J Gregg, et al.
Journal of Medicinal Chemistry|December 8, 2006
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunctionMeena V Patel, Teodozyj Kolasa, Kathleen Mortell, et al.
Journal of Medicinal Chemistry|January 24, 2012
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1Vince S C Yeh, David W A Beno, Sevan Brodjian, et al.
Molecular Cancer Therapeutics|March 31, 2021
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.
Pageof 66

Showing results (641-650 of 654) with videos related to

Sort By:
Pageof 66
Journal of Medicinal Chemistry|January 11, 2008
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitorGang Zhao, Andrew J Souers, Martin Voorbach, et al.
Bioorganic & Medicinal Chemistry|May 27, 2008
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic painIrene Drizin, Robert J Gregg, Marc J C Scanio, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylaminesAndrew J Souers, Rajesh R Iyengar, Andrew S Judd, et al.
Journal of Medicinal Chemistry|October 27, 2006
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safetyJohn K Lynch, Jennifer C Freeman, Andrew S Judd, et al.
International Journal for Parasitology|April 1, 2020
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learnedRyan Choi, Matthew A Hulverson, Wenlin Huang, et al.
Journal of Medicinal Chemistry|January 8, 2008
Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory painMichael E Kort, Irene Drizin, Robert J Gregg, et al.
Journal of Medicinal Chemistry|December 8, 2006
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunctionMeena V Patel, Teodozyj Kolasa, Kathleen Mortell, et al.
Journal of Medicinal Chemistry|January 24, 2012
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1Vince S C Yeh, David W A Beno, Sevan Brodjian, et al.
Molecular Cancer Therapeutics|March 31, 2021
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.
Pageof 66